Solace Therapeutics wins CE Mark for female incontinence device
October 1, 2009 by MassDevice staff
The Framingham, Mass.-based device maker's non-surgical intravesical system gets the OK to hit the market in the European Union.
Solace Therapeutics Inc. won CE Mark approval in the European Union for its intravesical system to treat female stress urinary incontinence.
The Framingham, Mass.-based medical device maker said its device is a small, quarter-sized balloon that floats inside the bladder. Inserted via catheter during an out-patient procedure, the balloon is designed to relieve the pressure fluctuations within the bladder that lead to incontinence.
- Login or register to post comments
-
Printer-friendly version
Permalink
NEWS
SurModics' Q1 sales, earnings plummet
First-quarter sales and earnings plummeted 81 and 93 percent, respectively, during the final three...
Sirona's Q1 net soars as sales grow 20 percent to $31 million
Sirona posted $31 million in first-quarter net income, up a whopping 460 percent, as Q1 sales rose to...
Ex-CoreValve CEO Lemaitre launches medical device equity fund
Former CoreValve CEO Dan Lemaitre will lead White Pine Medical, Essex Woodland Health's new...
Medtronic touts endoscopy sheath study
Medtronic Inc. touts a study showing endoscopic sheaths are jsut as effective in preventing infection...
Volcano Corp. and subsidiary loses court decision against Lightlab Imaging Inc.
Mass. jury rules that Axsun Technologies and Volcano violated terms of its contract with Westford,...
Top News Stories
SEARCH JOBS
RECENT BLOG POSTS
- Weekly Wireless Roundup: Three iPhone hospitals
- MedGadget's MedTech Monday: Avatar in the OR
- MedGadget's MedTech Monday: Flexible rubber sheets to power implantable devices?
- Weekly Wireless Roundup: Is Apple iPad the device healthcare has waited for?
- The case against EMRs
- Two agencies that could stand a temporary freeze
- Abiomed posts Impella procedure video
- MedGadget's MedTech Monday: Wireless sensor detects pH, glucose levels in exhaled breath
- MobiHealthNews Weekly Wireless Roundup: Four pharma companies test GlowCaps
- Clearing a path to reimbursement, Part II
Navigation
